Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Sinclair

Showing results (211-220 of 256) with videos related to

Pageof 26
Sort By:
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Journal of the American Academy of Dermatology|January 13, 2022
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasisChunlei Zhang, Kexiang Yan, Qingchun Diao, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|August 5, 2003
Morphological approach to hair disordersRodney Sinclair, Damian Jolley, Rica Mallari, et al.
American Journal of Clinical Dermatology|May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
The Australasian Journal of Dermatology|November 10, 2018
Treatment of alopecia areata: An Australian expert consensus statementWilliam C Cranwell, Vivien Wy Lai, Louise Photiou, et al.
Frontiers in Medicine|August 5, 2021
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled TrialJohn McCoy, Andy Goren, Flávio Adsuara Cadegiani, et al.
Pageof 26

Showing results (211-220 of 256) with videos related to

Sort By:
Pageof 26
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Journal of the American Academy of Dermatology|January 13, 2022
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasisChunlei Zhang, Kexiang Yan, Qingchun Diao, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|August 5, 2003
Morphological approach to hair disordersRodney Sinclair, Damian Jolley, Rica Mallari, et al.
American Journal of Clinical Dermatology|May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
The Australasian Journal of Dermatology|November 10, 2018
Treatment of alopecia areata: An Australian expert consensus statementWilliam C Cranwell, Vivien Wy Lai, Louise Photiou, et al.
Frontiers in Medicine|August 5, 2021
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled TrialJohn McCoy, Andy Goren, Flávio Adsuara Cadegiani, et al.
Pageof 26